Septerna (SEPN) Competitors $13.53 +1.06 (+8.50%) Closing price 07/23/2025 04:00 PM EasternExtended Trading$13.55 +0.02 (+0.15%) As of 05:59 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock SEPN vs. DNLI, BEAM, KNSA, BLTE, CNTA, VCEL, IRON, HRMY, IDYA, and CGONShould you be buying Septerna stock or one of its competitors? The main competitors of Septerna include Denali Therapeutics (DNLI), Beam Therapeutics (BEAM), Kiniksa Pharmaceuticals International (KNSA), Belite Bio (BLTE), Centessa Pharmaceuticals (CNTA), Vericel (VCEL), Disc Medicine (IRON), Harmony Biosciences (HRMY), IDEAYA Biosciences (IDYA), and CG Oncology (CGON). These companies are all part of the "pharmaceutical products" industry. Septerna vs. Its Competitors Denali Therapeutics Beam Therapeutics Kiniksa Pharmaceuticals International Belite Bio Centessa Pharmaceuticals Vericel Disc Medicine Harmony Biosciences IDEAYA Biosciences CG Oncology Septerna (NASDAQ:SEPN) and Denali Therapeutics (NASDAQ:DNLI) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, media sentiment, valuation, institutional ownership, earnings, dividends, analyst recommendations and profitability. Does the media favor SEPN or DNLI? In the previous week, Denali Therapeutics had 2 more articles in the media than Septerna. MarketBeat recorded 2 mentions for Denali Therapeutics and 0 mentions for Septerna. Denali Therapeutics' average media sentiment score of 0.77 beat Septerna's score of 0.00 indicating that Denali Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Septerna Neutral Denali Therapeutics Positive Do analysts rate SEPN or DNLI? Septerna currently has a consensus price target of $26.75, suggesting a potential upside of 97.71%. Denali Therapeutics has a consensus price target of $33.71, suggesting a potential upside of 132.99%. Given Denali Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Denali Therapeutics is more favorable than Septerna.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Septerna 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.80Denali Therapeutics 0 Sell rating(s) 1 Hold rating(s) 14 Buy rating(s) 2 Strong Buy rating(s) 3.06 Do insiders & institutionals believe in SEPN or DNLI? 92.9% of Denali Therapeutics shares are held by institutional investors. 4.3% of Septerna shares are held by company insiders. Comparatively, 12.5% of Denali Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Is SEPN or DNLI more profitable? Septerna's return on equity of 0.00% beat Denali Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets SepternaN/A N/A N/A Denali Therapeutics N/A -35.90%-32.41% Which has better earnings & valuation, SEPN or DNLI? Septerna has higher earnings, but lower revenue than Denali Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSepterna$1.08M558.24-$71.80MN/AN/ADenali Therapeutics$330.53M6.36-$422.77M-$2.67-5.42 SummaryDenali Therapeutics beats Septerna on 9 of the 13 factors compared between the two stocks. Get Septerna News Delivered to You Automatically Sign up to receive the latest news and ratings for SEPN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SEPN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SEPN vs. The Competition Export to ExcelMetricSepternaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$555.64M$2.99B$5.58B$9.42BDividend YieldN/A2.44%4.05%3.99%P/E RatioN/A21.2528.1520.08Price / Sales558.24253.30398.5583.94Price / CashN/A41.9636.1958.45Price / Book1.438.198.595.83Net Income-$71.80M-$55.10M$3.24B$258.27M7 Day Performance7.21%5.56%3.51%2.69%1 Month Performance26.33%18.19%10.96%12.91%1 Year PerformanceN/A7.32%35.08%21.81% Septerna Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SEPNSepterna1.1509 of 5 stars$13.53+8.5%$26.75+97.7%N/A$555.64M$1.08M0.00N/ADNLIDenali Therapeutics4.2113 of 5 stars$14.69+1.2%$33.71+129.5%-39.4%$2.13B$330.53M-5.50430Upcoming EarningsGap UpBEAMBeam Therapeutics2.0791 of 5 stars$21.17+0.0%$48.75+130.3%-26.9%$2.13B$63.52M-4.59510Analyst UpgradeAnalyst RevisionKNSAKiniksa Pharmaceuticals International3.4575 of 5 stars$28.80+2.5%$39.33+36.6%+3.2%$2.10B$423.24M-115.20220Positive NewsAnalyst ForecastBLTEBelite Bio1.7539 of 5 stars$63.58+0.6%$96.67+52.0%+24.4%$2.02BN/A-46.7510Negative NewsGap UpHigh Trading VolumeCNTACentessa Pharmaceuticals3.3587 of 5 stars$15.13+4.9%$27.89+84.3%+57.8%$2.02B$15M-8.36200Analyst ForecastInsider TradeHigh Trading VolumeVCELVericel3.8531 of 5 stars$39.82-0.3%$61.14+53.5%-23.7%$2.00B$238.54M1,327.78300Positive NewsUpcoming EarningsIRONDisc Medicine3.3787 of 5 stars$57.74+1.5%$96.70+67.5%+32.1%$2.00BN/A-14.7330Analyst ForecastHRMYHarmony Biosciences4.8492 of 5 stars$34.71+2.1%$51.33+47.9%+11.1%$1.99B$714.73M13.25200Positive NewsAnalyst ForecastAnalyst RevisionIDYAIDEAYA Biosciences4.2453 of 5 stars$22.58+0.4%$47.55+110.6%-44.9%$1.98B$7M-6.2980News CoverageAnalyst ForecastCGONCG Oncology2.4815 of 5 stars$25.90-3.1%$56.80+119.3%-23.3%$1.97B$1.14M-17.1561Gap Up Related Companies and Tools Related Companies DNLI Competitors BEAM Competitors KNSA Competitors BLTE Competitors CNTA Competitors VCEL Competitors IRON Competitors HRMY Competitors IDYA Competitors CGON Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SEPN) was last updated on 7/24/2025 by MarketBeat.com Staff From Our PartnersBuffett to put 90% of his money in this one stock?CPA and CFA says you have WAY too many stocks - just buy these 3 After years working at the biggest accoun...Altimetry | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredI was wrong about TrumpAddiction. Crime. Corruption. One devastating lie may be fueling it all. A new exposé reveals the hidden ca...Porter & Company | SponsoredFREE GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...GoldCo Precious Metals | SponsoredTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Septerna, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Septerna With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
